|||
Lead optimization is a critical phase in the development of Digital Therapeutics (DTx), particularly when a Best-in-Class (BIC) positioning is more promising than a First-in-Class (FIC) approach.
While true innovation may lead to untapped markets, optimizing existing interventions can achieve exceptional differentiation and superior clinical outcomes—much like atorvastatin, the seventh statin to market, which became the best-selling drug globally.
In this phase, we refine digital interventions—such as derivatives of neuromodulatory MOAs—using evidence-based iterations.
The goal is to improve therapeutic efficacy, enhance patient adherence, and reduce any implementation risks. By tailoring interventions for greater precision and impact, we pave the way for standout performance in competitive landscapes.
When the market is not untapped, lead optimization ensures that your digital therapeutic stands apart by becoming the most effective, user-friendly, and clinically validated option in its category.
This “atorvastatin” approach to become Best-in-Class drives success in competitive markets by prioritizing value over novelty.
Explore how our Lead Optimization methodology can transform promising hits into market-leading digital therapeutics.
Home > Solutions > DTx R&D > DTx Discovery > Lead Optimization
